Thus, while activating mutations of KRAS and inactivating mutations of RB1 and TP53 are typically absent in well-differentiated PNETs, they are commonly seen in both PDACs and pancreatic neuroendocrine carcinomas [29,33,34,35,36,37]. The gene discussed is KRAS; the disease is pancreatic endocrine carcinoma.